Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings

Sarikapan Wilailak,Karen KL Chan,Chi-An Chen,남주현,Kazunori Ochiai,Tar-Choon Aw,Subathra Sabaratnam,Sudarshan Hebbar,Jaganathan Sickan,Beth A Schodin,Chuenkamon Charakorn,Walfrido W Sumpaico 대한부인종양학회 2015 Journal of Gynecologic Oncology Vol.26 No.1

Results: A total of 414 women with a pelvic mass were enrolled in the study, of which 328 had documented ultrasound findings. The risk prediction model that contained HE4, menopausal status, and ultrasound findings exhibited the best performance compared to models with CA-125 alone, or a combination of CA-125 and HE4. This model classified 77.2% of women with ovarian cancer as medium or high risk, and 86% of women with benign disease as very-low, low, or medium-low risk. This model exhibited better sensitivity than ROMA, but ROMA exhibited better specificity. Both models performed better than CA-125 alone. Objective: The purpose of this study was to develop a risk prediction score for distinguishing benign ovarian mass from malignant tumors using CA-125, human epididymis protein 4 (HE4), ultrasound findings, and menopausal status. The risk prediction score was compared to the risk of malignancy index and risk of ovarian malignancy algorithm (ROMA). Methods: This was a prospective, multicenter (n=6) study with patients from six Asian countries. Patients had a pelvic mass upon imaging and were scheduled to undergo surgery. Serum CA-125 and HE4 were measured on preoperative samples, and ultrasound findings were recorded. Regression analysis was performed and a risk prediction model was developed based on the significant factors. A bootstrap technique was applied to assess the validity of the HE4 model. Results: A total of 414 women with a pelvic mass were enrolled in the study, of which 328 had documented ultrasound findings. The risk prediction model that contained HE4, menopausal status, and ultrasound findings exhibited the best performance compared to models with CA-125 alone, or a combination of CA-125 and HE4. This model classified 77.2% of women with ovarian cancer as medium or high risk, and 86% of women with benign disease as very-low, low, or medium-low risk. This model exhibited better sensitivity than ROMA, but ROMA exhibited better specificity. Both models performed better than CA-125 alone. Conclusion: Combining ultrasound with HE4 can improve the sensitivity for detecting ovarian cancer compared to other algorithms.

Epidemiologic report of gynecologic cancer in Thailand

Sarikapan Wilailak 대한부인종양학회 2009 Journal of Gynecologic Oncology Vol.20 No.2

Cancer has been the most common cause of death in Thailand from 2002 (65.4/100,000/year in 2002). With regard to leading cancers in Thailand for female population, the highest incidence falls into cervical cancer (25/100,000/ year) followed by breast, liver and bile duct, bronchus and lung, colon and rectum, and ovarian cancer. In 2003, there were 6,243 new cases of cervical cancer with the death of 2,620 women. Therefore, in Thailand, seven women die from cervical cancer each day. However, the incidence of cervical cancer in Thailand is decreasing. The important factor contributed to this decreasing is the implement of Thailand dual-track strategy cervical screening program using both Pap smear and visual inspection with acetic acid (VIA)-cryotherapy. Learning about the epidemiologic data of gynecologic cancer could raise public awareness and play a part in establishing measures for prevention, control and treatment of the cancer which will contribute to the better health of women, and of course, decrease the expense used in various modalities of treatment. Cancer has been the most common cause of death in Thailand from 2002 (65.4/100,000/year in 2002). With regard to leading cancers in Thailand for female population, the highest incidence falls into cervical cancer (25/100,000/ year) followed by breast, liver and bile duct, bronchus and lung, colon and rectum, and ovarian cancer. In 2003, there were 6,243 new cases of cervical cancer with the death of 2,620 women. Therefore, in Thailand, seven women die from cervical cancer each day. However, the incidence of cervical cancer in Thailand is decreasing. The important factor contributed to this decreasing is the implement of Thailand dual-track strategy cervical screening program using both Pap smear and visual inspection with acetic acid (VIA)-cryotherapy. Learning about the epidemiologic data of gynecologic cancer could raise public awareness and play a part in establishing measures for prevention, control and treatment of the cancer which will contribute to the better health of women, and of course, decrease the expense used in various modalities of treatment.

The epidemiologic status of gynecologic cancer in Thailand

Sarikapan Wilailak,Nuttapong Lertchaipattanakul 대한부인종양학회 2016 Journal of Gynecologic Oncology Vol.27 No.6

Between the years of 2010-2012, it was estimated there were a total of 112,392 new cases of cancers in Thailand, thus, the total age-standardized rate (ASR) per 100,000 is 137.6. In regards to the most prevalent types of cancer in female, breast cancer has the highest ASR, followed by cervical cancer (ASR=14.4); liver and bile duct cancer; colon and rectum cancer; trachea, bronchus and lung cancer; ovarian cancer (ASR=6.0); thyroid cancer; non-Hodgkin lymphoma and uterine cancer (ASR=4.3). The trend of cervical cancer in Thailand is decreasing, one key factor in making this possible was the employment of dual tract strategy (Pap smear and visual inspection with acetic acid [VIA]) by the government in 2005. In the future, the government is also considering integrating human papillomavirus (HPV) vaccination into the national immunization program, which may assist in the prevention of cervical cancer. By studying the statistical data of gynecologic cancer, it will be possible to formulate measures for the prevention, control and treatment of gynecologic cancer. Eventually, it will potentially improve the quality of life (QoL) of patients as well as decrease the mortality rate caused by gynecologic cancer.

Quality of life in gynecologic cancer survivors compared to healthy check-up women

Sarikapan Wilailak,Arb-aroon Lertkhachonsuk,Nawaporn Lohacharoenvanich,Suteera Chukkul Luengsukcharoen,Manmana Jiraharas,Puchong Likitanasombat,Suwannee Sirllerttrakul 대한부인종양학회 2011 Journal of Gynecologic Oncology Vol.22 No.2

Objective: The primary objective of this study was to compare quality of life of disease-free patients after therapy for gynecologic malignancies at follow-up in comparison with healthy check-up patients. Our second objective was to assess correlation between demographic data, disease and treatment factors and quality of life scores. Methods: Patients completed the Functional Assessment of Cancer Therapy-General (FACT-G) quality of life questionnaire at least 6 months after treatment for a gynecologic malignancy. Responses were compared to unmatched healthy women who were seen for standard gynecologic screening examinations. Statistical calculation was done using chi-squared tests, Wilcoxon rank-sum, and Kruskal-Wallis one-way analysis and Spearman rank correlations. Factors associated with FACT-G scores were evaluated using univariate and multivariate analyses. Results: Eight hundred and seventy patients were recruited. The median time since therapy was 61 months (range, 6 to 173 months). The overall FACT-G scores were higher in the patient group than in the healthy group (p<0.05). The scores of each subscale measuring physical, functional, social/family and emotional well-being were also higher in the patient group (p<0.05). Multivariate analysis revealed correlation between Eastern Cooperative Oncology Group performance status, educational level, care giver, presence of economic problems and FACT-G scores. Conclusion: The quality of life scores were higher in gynecologic cancer patients after treatment. And the factors that associated with the higher score in the patient group are having husband as a caregiver, no financial problem, Eastern Cooperative Oncology Group score 0 or 1 and having high school or higher education. Objective: The primary objective of this study was to compare quality of life of disease-free patients after therapy for gynecologic malignancies at follow-up in comparison with healthy check-up patients. Our second objective was to assess correlation between demographic data, disease and treatment factors and quality of life scores. Methods: Patients completed the Functional Assessment of Cancer Therapy-General (FACT-G) quality of life questionnaire at least 6 months after treatment for a gynecologic malignancy. Responses were compared to unmatched healthy women who were seen for standard gynecologic screening examinations. Statistical calculation was done using chi-squared tests, Wilcoxon rank-sum, and Kruskal-Wallis one-way analysis and Spearman rank correlations. Factors associated with FACT-G scores were evaluated using univariate and multivariate analyses. Results: Eight hundred and seventy patients were recruited. The median time since therapy was 61 months (range, 6 to 173 months). The overall FACT-G scores were higher in the patient group than in the healthy group (p<0.05). The scores of each subscale measuring physical, functional, social/family and emotional well-being were also higher in the patient group (p<0.05). Multivariate analysis revealed correlation between Eastern Cooperative Oncology Group performance status, educational level, care giver, presence of economic problems and FACT-G scores. Conclusion: The quality of life scores were higher in gynecologic cancer patients after treatment. And the factors that associated with the higher score in the patient group are having husband as a caregiver, no financial problem, Eastern Cooperative Oncology Group score 0 or 1 and having high school or higher education.

The 6th Biennial Meeting of the Asian Society of Gynecologic Oncology, October 10th to 12th, 2019

Kittipat Charoenkwan,Sarikapan Wilailak 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.1

.

TGCS's Annual Meeting, August 10-12, 2012

Duangmani Thanapprapasr,Sarikapan Wilailak 대한부인종양학회 2012 Journal of Gynecologic Oncology Vol.23 No.4

Asian Society of Gynecologic Oncology International Workshop 2018

공태욱,유희석,김승철,Takayuki Enomoto,Jin Li,Kenneth H. Kim,심승혁,Peng-Hui Wang,Suwanit Therasakvichya,Yusuke Kobayashi,이마리아,Ting-Yan Shi,이신화,Mikio Mikami,Satoru Nagase,임명철,Jianliu Wang,Sarikapan Wilailak,김상운,홍숙 대한부인종양학회 2019 Journal of Gynecologic Oncology Vol.30 No.2

The Asian Society of Gynecologic Oncology International Workshop 2018 on gynecologic oncology was held in the Ajou University Hospital, Suwon, Korea on the 24th to 25th August 2018. The workshop was an opportunity for Asian doctors to discuss the latest findings of gynecologic cancer, including cervical, ovarian, and endometrial cancers, as well as the future of fertility-sparing treatments, minimally invasive/radical/debulking surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. Clinical guidelines and position statement of Asian countries were presented by experts. Asian clinical trials for gynecologic cancers were reviewed and experts emphasized the point that original Asian study is beneficial for Asian patients. In Junior session, young gynecologic oncologists presented their latest research on gynecologic cancers.

Asian society of gynecologic oncology workshop 2010

서동훈,김재원,Mohamad Farid Aziz,Uma K. Devi,Hextan Y. S. Ngan,남주현,김승철,Tomoyasu Kato,유희석,Shingo Fujii,이윤순,김종혁,김태중,김영태,Kung-Liahng Wang,이택상,Kimio Ushijima,신상구,Yin Nin Chia,Sarikapan Wilailak,박상윤,Hidetaka Kat 대한부인종양학회 2010 Journal of Gynecologic Oncology Vol.21 No.3

This workshop was held on July 31-August 1, 2010 and was organized to promote the academic environment and to enhance the communication among Asian countries prior to the 2nd biennial meeting of Australian Society of Gynaecologic Oncologists (ASGO), which will be held on November 3-5, 2011. We summarized the whole contents presented at the workshop. Regarding cervical cancer screening in Asia, particularly in low resource settings, and an update on human papillomavirus (HPV) vaccination was described for prevention and radical surgery overview,fertility sparing and less radical surgery, nerve sparing radical surgery and primary chemoradiotherapy in locally advanced cervical cancer, were discussed for management. As to surgical techniques, nerve sparing radical hysterectomy, optimal staging in early ovarian cancer, laparoscopic radical hysterectomy, one-port surgery and robotic surgery were introduced. After three topics of endometrial cancer, laparoscopic surgery versus open surgery, role of lymphadenectomy and fertility sparing treatment, there was a special additional time for clinical trials in Asia. Finally,chemotherapy including neo-adjuvant chemotherapy, optimal surgical management, and the basis of targeted therapy in ovarian cancer were presented.